Treatment Patterns and Resource Use After Osimertinib Discontinuation in Patients with EGFR + Metastatic NSCLC.
Elizabeth MarrettWinghan Jacqueline KwongJinlin SongAmeur ManceurSelvam SendhillEric Wu
Published in: Oncology and therapy (2024)
The duration of the LOT following osimertinib was short and associated with tolerability issues underscoring a high unmet need for new therapies to address EGFR TKI resistance.